Document Type

Article

Publication Date

2020

Keywords

combination therapy, immunotherapy, metastatic melanoma, oncolytic virus, real-world evidence, talimogene laherparepvec, T-VEC

Abstract

Aim: Talimogene laherparepvec (T-VEC) is an intralesional therapy for unresectable, metastatic melanoma. T-VEC real-world use in the context of anti-PD1-based therapy requires further characterization.

Materials & methods: A retrospective review of T-VEC use from 1 January 2017 and 31 March 2018 for melanoma patients was conducted at seven US institutions.

Results: Among 83 patients, three categories of T-VEC and anti-PD-1 therapy were identified: T-VEC used without anti-PD-1 (n = 29, 35%), T-VEC after anti-PD-1-based therapy (n = 22, 27%) and concurrent T-VEC and anti-PD-1-based therapy (n = 32, 39%). 25% of patients discontinued T-VEC therapy due to no remaining injectable lesions, 37% discontinued T-VEC due to progressive disease. Discontinuation of T-VEC did not differ by anti-PD-1-based therapy use or timing.

Conclusion: In real-world settings, T-VEC may be used concurrently with or after anti-PD-1-based therapy.

Digital Object Identifier (DOI)

https://doi.org/10.2217/mmt-2020-0005

Rights Information

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Citation / Publisher Attribution

Melanoma Management, v. 7, issue 2, art. 0005

Was this content written or created while at USF?

Yes

Included in

Oncology Commons

COinS